Moderna CEO Stéphane Bancel highlights cancer vaccine progress and warns of China's growing biotechnology threat to the U.S.
Moderna CEO Stéphane Bancel reported positive Phase 3 melanoma trial results for a personalized mRNA cancer treatment developed in partnership with Merck. While the company's stock surged following these results, Bancel emphasized the importance of maintaining American leadership in biotechnology. He warned that China is aggressively investing in the sector as a strategic emerging industry, posing a significant challenge to U.S. dominance. To counter this, Bancel noted that Moderna is expanding manufacturing operations in Massachusetts to ensure advanced medicines are produced on American soil rather than relying on foreign supply chains. He advocated for the government to take risks on innovative medicine, noting that while the HHS wound down some mRNA vaccine projects, the administration announced a shift toward greater scientific scrutiny and redirected resources toward promising technologies. Bancel highlighted that mRNA technology has proven its utility beyond infectious diseases, positioning Moderna to expand into rare genetic diseases by the end of the year.